Stryker elects James E. Davis to board effective 2027
Davis will receive compensation consistent with Stryker’s other non-employee directors; he had not been appointed to a board committee at the time of the report.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Stryker Corporation increased its authorized board size from 11 to 12 directors and elected James E. Davis to fill the vacancy, effective January 1, 2027. A November 9 press release described Davis as a nominee for election. He is chairman, CEO and president of Quest Diagnostics; Stryker said he had not been appointed to a board committee at the time of the report.
Davis will receive compensation consistent with Stryker’s other non-employee directors, as described in its 2026 proxy statement. Stryker also said it will enter into its form of director indemnification agreement with him. He has served as Quest Diagnostics’ CEO and president since November 2022 and became its chairman in April 2023.
8-K Event Classification
Key Figures
Key Terms
authorized directors regulatory
non-employee directors regulatory
indemnification agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does James E. Davis join Stryker’s board?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On November 3, 2026, the Board of Directors of Stryker Corporation (the “Company”) increased the number of authorized directors from 11 to 12 and elected James E. Davis to fill the resulting vacancy. Mr. Davis’s election will become effective on January 1, 2027, and he has not been appointed to any committee of the Board at this time.
Mr. Davis has been CEO and President of Quest Diagnostics (“Quest”) since November 2022 and assumed the role of Chairman of the Quest Board in April 2023. Mr. Davis joined Quest in 2013 as Senior Vice President, Diagnostic Services and was named Senior Vice President, Operations in February 2014. Before joining Quest, he served as CEO of InSightec, Inc., a global medical device company. Prior to that, Mr. Davis spent two decades in senior management roles across General Electric’s healthcare and aviation businesses, including five years leading General Electric’s MRI business. Before General Electric, Mr. Davis led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc.
Mr. Davis will be compensated for his services consistent with the Company’s other non-employee directors, as described in the Company’s proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2026. In connection with his election to the Company’s Board of Directors, the Company will enter into the form of indemnification agreement for directors, a copy of which is filed as Exhibit 10(xxviii) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 11, 2026, with Mr. Davis.
| Item 7.01 | Regulation FD Disclosure. |
On November 9, 2026, the Company issued a press release announcing the election of Mr. Davis as a director as described in Item 5.02 above, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing of the Company, whether made before, on, or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits | |
| 99.1 Press Release dated November 9, 2026. | ||
| 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL | ||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STRYKER CORPORATION | ||||||
| (Registrant) | ||||||
| Dated: November 9, 2026 | By: | /s/ Tina S. French | ||||
| Name: | Tina S. French | |||||
| Title: | Corporate Secretary | |||||
Exhibit 99.1
1941 Stryker Way
Portage, MI 49002
| www.stryker.com | November 9, 2026 |
Press release
Stryker announces intention to nominate Jim Davis to board of directors
PORTAGE, Mich. – Nov. 9, 2026 – Stryker (NYSE:SYK) announced that its board of directors has nominated Jim Davis for election to the company’s board, effective Jan. 1, 2027.
Jim serves as Chairman, CEO and President of Quest Diagnostics. He brings extensive leadership experience across healthcare, medical technology and global operations.
Before joining Quest, Jim served as CEO of InSightec, Inc., a global medical device company. Prior to that, he spent two decades in senior management roles across General Electric’s healthcare and aviation businesses, including five years leading GE’s MRI business. Before GE, Jim led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc.
Jim holds a master’s degree in management from the MIT Sloan School of Management, a master’s degree in science from MIT and a bachelor’s degree in aeronautical engineering from the University of Michigan.
“We are pleased to have Jim as a nominee for our board,” said Kevin Lobo, Chair and CEO, Stryker. “His deep healthcare experience, operational leadership and understanding of medical technology will be a strong addition as we continue to advance Stryker’s strategy and mission.”
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or nick.mead@stryker.com
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com